Skip to main content
← Science / Explained

SERIES: MYTHS READ AGAINST THE SCIENCE

Infertility is not an established GLP-1 risk, pregnancy timing is the real concern

What Shapes Fertility

Fertility is shaped by weight, metabolic health, menstrual regularity, ovarian function, age, sleep, other medications, and underlying conditions. For people with weight-related fertility problems, weight loss can support a return of regular cycles.

For people in a steep calorie deficit, fertility signals can shift the other way. That's a property of the deficit, not specific to these peptides.

What the Label Says

Semaglutide labels such as Wegovy and Ozempic point to stopping at least two months before a planned pregnancy because of the long washout period.

The signal in the label is a planning window, not a proven human infertility outcome. Animal data suggest the pathway can affect ovulation biology at weight-loss-associated doses, so the honest claim is narrower: human infertility is not an established label outcome.

What this means

References1 sources

How to read these sources

This article uses primary sources and reviews to separate mechanism, human evidence, and context.

Official LabelRegulator documents
Show 4 more source types
Human TrialStudies in people
ReviewExpert synthesis
MechanismCell and pathway logic
Public UpdateNews or announcements
  1. Official Label

    FDA-approved prescribing information (Wegovy)

    U.S. Food and Drug Administration / Novo Nordisk

    Novo Nordisk · 2026 WEGOVY (semaglutide) prescribing information: 8.1 Pregnancy and 8.3 Females and Males of Reproductive Potential Read source

    Used Here For

    Grounding the infertility question in the approved label's pregnancy and specific-populations section.

    Good For

    The FDA-approved facts on labeled use during pregnancy planning.

    Not For

    Personal fertility or family-planning advice.

    FDA-approved labeling, DailyMed (National Library of Medicine), updated June 18, 2026